265 related articles for article (PubMed ID: 23643669)
1. Progesterone is not the same as 17α-hydroxyprogesterone caproate: implications for obstetrical practice.
Romero R; Stanczyk FZ
Am J Obstet Gynecol; 2013 Jun; 208(6):421-6. PubMed ID: 23643669
[No Abstract] [Full Text] [Related]
2. Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety.
O'Brien JM; Lewis DF
Am J Obstet Gynecol; 2016 Jan; 214(1):45-56. PubMed ID: 26558340
[TBL] [Abstract][Full Text] [Related]
3. What agent should be used to prevent recurrent preterm birth: 17-P or natural progesterone?
Hall NR
Obstet Gynecol Clin North Am; 2011 Jun; 38(2):235-46, ix-x. PubMed ID: 21575799
[TBL] [Abstract][Full Text] [Related]
4. Is 17α-hydroxyprogesterone caproate contraindicated in twin gestations?
Romero R; Conde-Agudelo A
BJOG; 2015 Jan; 122(1):6-7. PubMed ID: 25280114
[No Abstract] [Full Text] [Related]
5. The association between 17-hydroxyprogesterone caproate use and postpartum hemorrhage.
Miller ES; Sakowicz A; Roy A; Liu LY; Yee LM
Am J Obstet Gynecol MFM; 2019 May; 1(2):144-147. PubMed ID: 32914089
[TBL] [Abstract][Full Text] [Related]
6. Association of 17α-Hydroxyprogesterone Caproate and Risk of Infection.
Mainiero AD; Rouse DJ; Lopes V; Hughes BL
Obstet Gynecol; 2015 Jul; 126(1):103-8. PubMed ID: 26241262
[TBL] [Abstract][Full Text] [Related]
7. 17-alpha hydroxyprogesterone caproate for preterm birth prevention: Where have we been, how did we get here, and where are we going?
Manuck TA
Semin Perinatol; 2017 Dec; 41(8):461-467. PubMed ID: 28947068
[TBL] [Abstract][Full Text] [Related]
8. Vaginal Progesterone Is Associated with Intrahepatic Cholestasis of Pregnancy.
Tsur A; Leonard SA; Kan P; Datoc IA; Girsen AI; Shaw GM; Stevenson DK; El-Sayed YY; Druzin ML; Blumenfeld YJ
Am J Perinatol; 2023 Aug; 40(11):1158-1162. PubMed ID: 37100422
[TBL] [Abstract][Full Text] [Related]
9. Immune effects of 17α-hydroxyprogesterone caproate.
Al-Lami RA
Am J Obstet Gynecol; 2022 Oct; 227(4):671-675. PubMed ID: 35779586
[No Abstract] [Full Text] [Related]
10. What we have learned about the role of 17-alpha-hydroxyprogesterone caproate in the prevention of preterm birth.
Caritis SN; Feghali MN; Grobman WA; Rouse DJ;
Semin Perinatol; 2016 Aug; 40(5):273-80. PubMed ID: 27105940
[TBL] [Abstract][Full Text] [Related]
11. 17α-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: a randomized controlled trial.
Lim AC; Schuit E; Bloemenkamp K; Bernardus RE; Duvekot JJ; Erwich JJHM; van Eyck J; Groenwold RHH; Hasaart THM; Hummel P; Kars MM; Kwee A; van Oirschot CM; van Pampus MG; Papatsonis D; Porath MM; Spaanderman ME; Willekes C; Wilpshaar J; Mol BWJ; Bruinse HW
Obstet Gynecol; 2011 Sep; 118(3):513-520. PubMed ID: 21860279
[TBL] [Abstract][Full Text] [Related]
12. Deus ex Makena?
Silver RM; Cunningham FG
Obstet Gynecol; 2011 Jun; 117(6):1263-1265. PubMed ID: 21471852
[No Abstract] [Full Text] [Related]
13. Effect of 17alpha-hydroxyprogesterone caproate on glucose intolerance in pregnancy.
Waters TP; Schultz BAH; Mercer BM; Catalano PM
Obstet Gynecol; 2009 Jul; 114(1):45-49. PubMed ID: 19546757
[TBL] [Abstract][Full Text] [Related]
14. 17 α-hydroxyprogesterone caproate (Makena®): a guide to its use in the prevention of preterm birth.
Hines M; Lyseng-Williamson KA; Deeks ED
Clin Drug Investig; 2013 Mar; 33(3):223-7. PubMed ID: 23413110
[TBL] [Abstract][Full Text] [Related]
15. Prevention of preterm delivery with 17-hydroxyprogesterone caproate: pharmacologic considerations.
Feghali M; Venkataramanan R; Caritis S
Semin Perinatol; 2014 Dec; 38(8):516-22. PubMed ID: 25256193
[TBL] [Abstract][Full Text] [Related]
16. Prevention of Preterm Labor with 17α-Hydroxyprogesterone (17OHP) Caproate: A Comparison of Adverse Drug Reaction Rates between Compounded and Commercial Formulations.
Stone RH; Bobowski C; Milikhiker N; Anguiano RH; Mastrogiannis D
Am J Perinatol; 2017 Dec; 34(14):1436-1441. PubMed ID: 28704849
[No Abstract] [Full Text] [Related]
17. Role of progestogens for the prevention of premature birth.
Schindler AE
J Steroid Biochem Mol Biol; 2005 Dec; 97(5):435-8. PubMed ID: 16198556
[TBL] [Abstract][Full Text] [Related]
18. Operationalizing 17α-Hydroxyprogesterone Caproate to Prevent Recurrent Preterm Birth: Definitions, Barriers, and Next Steps.
Stringer EM; Vladutiu CJ; Batra P; Stringer JSA; Menard MK
Obstet Gynecol; 2016 Dec; 128(6):1397-1402. PubMed ID: 27824772
[TBL] [Abstract][Full Text] [Related]
19. 17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study.
Nelson DB; McIntire DD; McDonald J; Gard J; Turrichi P; Leveno KJ
Am J Obstet Gynecol; 2017 Jun; 216(6):600.e1-600.e9. PubMed ID: 28223163
[TBL] [Abstract][Full Text] [Related]
20. The end is where we start from: withdrawal of 17-alpha hydroxyprogesterone caproate to prevent recurrent preterm birth.
Nelson DB; Herrera CL; McIntire DD; Cunningham FG
Am J Obstet Gynecol; 2024 Jan; 230(1):1-9. PubMed ID: 37798189
[No Abstract] [Full Text] [Related]
[Next] [New Search]
